+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997



Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997



Leukemia Research 30(7): 823-827



Randomized trials of substituting high-dose cytarabine (HiDAC) for standard dose cytarabine (SDAC) during induction therapy for newly diagnosed AML have not demonstrated an improvement in the complete remission (CR) rate. Phase II trials of the scheduled administration of HiDAC after SDAC suggest an improved outcome. The hematological complications of intensification are considerable. GM-CSF after chemotherapy improved the survival of older patients in a randomized trial. Recombinant human interleukin 11, a thrombopoietic cytokine, reduced the incidence of chemotherapy-induced thrombocytopenia in patients with solid tumors. Therefore, 34 patients were treated, with newly diagnosed AML less than 56 years of age, with daunorubicin 45 mg/m2 on days 1-3, cytarabine 100mg/m2 days 1-7 and cytarabine 2g/m2 for 12 h on days 8-10 (7+3+3). rhIL-11 (50 microg/kg/day,) and GM-CSF (250 microg/kg/day) were administered subcutaneously from day 11 until recovery. The complete remission rate was 59% (90% C.I. 43-73%). The median time to recovery of neutrophils to >500 and platelets to > or =20,000 microl(-1) was 27 days (95% C.I. 27-30 days) and 25 days (95% C.I. 24-29 days), respectively. The trial does not confirm the high CR rate observed in phase II trials, despite optimal supportive care.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012410506

Download citation: RISBibTeXText

PMID: 16413056

DOI: 10.1016/j.leukres.2005.11.006


Related references

A phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia receiving high-dose cytarabine during induction ECOG 3997. Blood 96(11 Part 1): 323a, 2000

Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia. Leukemia 15(9): 1331-1338, 2001

Effects of recombinant human granulocyte-macrophage colony stimulating factor in newly diagnosed high risk patients with acute myeloid leukemia. Proceedings of the American Association for Cancer Research Annual Meeting 36: 221, 1995

High-dose cytarabine and recombinant human granulocyte colony-stimulating factor for the treatment of resistant acute myelogenous leukemia. Leukemia and Lymphoma 20(5-6): 427-434, 1996

Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 77(4): 700-711, 1991

A phase II trial of recombinant human granulocyte macrophage-colony stimulating factor recombinant human interleukin-4 used as combination therapy for subjects with hormone refractory prostate cancer. Journal of Investigative Medicine 50(2): 166A, 2002

Phase i study of subcutaneous human recombinant granulocyte macrophage colony stimulating factor gmcsf hoechst behring in patients with solid tumors. Proceedings of the American Association for Cancer Research Annual Meeting 31: 198, 1990

Experimental basis for the use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with acute myeloid leukemia. Seminars in Oncology 21(6 Suppl 16): 39-43, 1994

Recombinant human interleukin 3 and recombinant human granulocyte macrophage colony stimulating factor administered in vivo after high dose cyclophosphamide cancer chemotherapy effect on hematopoiesis and microenvironment in human bone marrow. Blood 79(10): 2610-2619, 1992

Double-blind, placebo-controlled trial of daunorubicin and cytarabine with or without recombinant human granulocyte colony-stimulating factor in elderly patients with acute myeloid leukemia: economic evaluation with attention to inpatient and outpatient resource utilization. Journal of the National Cancer Institute. Monographs 1995(19): 37-40, 1995

Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 78(5): 1190-1197, 1991

Effects of recombinant human granulocyte-macrophage colony stimulating factor on apoptosis and cell cycle kinetics in newly diagnosed high risk patients with acute myeloid leukemia. Blood 84(10 Suppl. 1): 586A, 1994

Effect of recombinant human growth factors: recombinant human interleukin-6, recombinant human granulocyte-macrophage colony-stimulating-factor and recombinant human erythropoietin on normal human hematopoietic progenitor cells. Zhonghua Nei Ke Za Zhi 33(5): 298-301, 1994

In vivo administration of recombinant human granulocyte/macrophage colony-stimulating factor in acute lymphoblastic leukemia patients receiving purged autografts. Blood 73(3): 849-857, 1989

Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in acute myeloid leukemia evolving from myelodysplastic syndromes: a pilot study. Leukemia 8(10): 1631-1639, 1994